Current Psoriasis Efficacy Outcome Measures in Clinical Trials

Abstract

This review sought to examine currently used psoriasis efficacy outcome measures. In particular, we wanted to know what outcome measures are currently being used most frequently, in addition to the advantages and disadvantages of each outcome measure. In the past year, Psoriasis Area and Severity Index (PASI) was the most frequently used outcome measure in phase III and IV clinical trials evaluating psoriasis treatments. PASI scores were also the most frequently used primary outcome measure. Psoriasis Scalp Severity Index (PSSI) was the most commonly utilized regional physician reported outcome measure and Dermatology Quality of Life Index (DLQI) was the most commonly used patient reported outcome. It is important for clinical trials to utilize outcome measures that are both accurate and take into account patients’ perspectives. Standardization of outcome measures will allow for better comparison of treatments across clinical trials.